SIGN UP
LOG IN
News
FBIO
1.780
-1.66%
-0.030
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 1d ago
Weekly Report: what happened at FBIO last week (0408-0412)?
Weekly Report · 4d ago
Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments
TipRanks · 04/09 10:17
Weekly Report: what happened at FBIO last week (0401-0405)?
Weekly Report · 04/08 09:40
Weekly Report: what happened at FBIO last week (0325-0329)?
Weekly Report · 04/01 09:40
Fortress Biotech Q4 EPS $(0.53) Beats $(1.97) Estimate, Sales $19.95M Beat $14.89M Estimate
Fortress Biotech reported quarterly losses of $0.53 per share. The company reported quarterly sales of $19.95 million which beat the analyst consensus estimate of $14.89 million. Fortress Biotech also reported a 55.83 percent increase in sales from the same period last year.
Benzinga · 03/29 03:33
Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary
Fortress Biotech Inc reports results for the quarter ended in December. Revenue rose 21.6% to $19.95 million from a year ago. The company reported a quarterly adjusted loss of 53 cents per share. The mean expectation of five analysts was for a loss of $1.97.
Reuters · 03/28 23:25
Fortress Biotech GAAP EPS of -$8.47 beats by $0.64, revenue of $84.51M beats by $4.83M
Earnings News Fortress Biotech GAAP EPS of -$8.47 beats by $0.64, revenue of $84.51M beats by $4.83M. The company posted a quarterly loss of $1.07 per share.
Seeking Alpha · 03/28 20:57
Press Release: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024.
Dow Jones · 03/28 20:05
Press Release: Fortress Biotech Reports 2023 -2-
Fortress Biotech is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders. The company has seven marketed prescription pharmaceutical products and over 25 programs in development. Fortress has established partnerships with some of the world's leading academic research institutions.
Dow Jones · 03/28 20:05
Mustang Bio stock climbs 9% amid drug development update
Mustang Bio, Inc. Stock climbs 9% amid drug development update. Company plans to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. The drug candidate is currently in Phase 1/2 clinical trials for leukemia and lymphoma. Mustang was founded by Fortress Biotech (FBIO)
Seeking Alpha · 03/28 15:09
Fortress Biotech Inc <FBIO.OQ> expected to post a loss of $1.97 a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of $1.97 a share. The company is expected to report a 9.2% decrease in quarterly revenue to $14.894 million. Wall Street expects the company to report results on March 28.
Reuters · 03/26 11:02
Weekly Report: what happened at FBIO last week (0318-0322)?
Weekly Report · 03/25 09:41
Press Release: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics reports full-year 2023 financial results and recent corporate highlights. Checkpoint submitted a BLA to the FDA seeking approval of cosibelimab in January 2023. The FDA issued a complete response letter to Checkpoint in December 2023 for deficiencies in the company's manufacturing process. The company is working to address the deficiencies and is targeting marketing approval before the end of 2024. The Company is a clinical-stage immunotherapy company.
Dow Jones · 03/22 12:30
Press Release: Checkpoint Therapeutics Reports -2-
Delay achievement of those milestones. The information contained in this press release is not intended to be viewed in its totality. This press release and prior releases are available at www.checkpointtherapeutics.com. Checkpoint Therapeutics, Inc. Has no obligation to update any forward-looking statements. The company's financial results for the quarter ended December 31, 2013 are reported on its website.
Dow Jones · 03/22 12:30
Press Release: Journey Medical Corporation -3-
The Company's net loss per common share is $0.21 for the quarter. The Company has included certain non-GAAP measures in this press release. The Company's operating expenses include the cost of goods sold and the impairment of intangible assets. The company has a net loss of $18.2 million.
Dow Jones · 03/21 20:01
Press Release: Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022. New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024. Company to hold conference call today at 4:30 p.m. ET.
Dow Jones · 03/21 20:01
Fortress Biotech Initiated at Buy by Alliance Global Partners
Dow Jones · 03/19 12:30
Fortress Biotech Price Target Announced at $5.00/Share by Alliance Global Partners
Dow Jones · 03/19 12:30
Alliance Global Partners Initiates Coverage On Fortress Biotech with Buy Rating, Announces Price Target of $5
Benzinga · 03/19 12:20
More
Webull provides a variety of real-time FBIO stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).